Complex/variant translocations in chronic myelogenous leukemia (CML): genesis and prognosis with 4 new cases

被引:1
作者
Mendiola, Christina [1 ]
Ortega, Veronica [1 ]
Tonk, Vijay S. [2 ]
Coviello, Jean M. [3 ]
Velagaleti, Gopalrao [1 ]
机构
[1] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA
[2] Texas Tech Univ, Dept Pediat, Lubbock, TX 79409 USA
[3] San Antonio Mil Med Ctr, Dept Pathol, San Antonio, TX USA
关键词
BCR/ABL; Variant translocation; CML; D-FISH; Complex rearrangement; CHRONIC MYELOID-LEUKEMIA; VARIANT TRANSLOCATIONS; CHROMOSOMES; EVOLUTION; PH1;
D O I
10.1016/j.yexmp.2014.06.004
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
In 5-10% of cases with CML, variant or complex translocations (CT) are seen that may result in atypical fluorescence in situ hybridization signal patterns. Dual color, dual fusion fluorescence in situ hybridization (D-FISH) patterns are instrumental in identifying the genesis of these CT, but their prognostic implications remain controversial. The most common mechanism is a two-step process in which a standard two-way translocation (9;22) is followed by subsequent rearrangements involving other chromosomes. The second common mechanism is the one-step process wherein breakage occurs simultaneously on different chromosomes leading to CT. The typical D-FISH pattern seen with the one-step mechanism is 1F2G2R, while the pattern for the two-step mechanism can be variable (2F1G1R, 1F1G1R, 1F1G2R, 1F2G1R, etc.). We have studied 4 cases of CT using metaphase FISH with triple color, dual fusion ASS1, ABL1 and BCR probes to understand the genesis of these CT. All the patients were treated with imatinib, but only patients 3 and 4 showed remission. Our results indicate that the CT in cases 1,3 and 4 arose from a one-step mechanism and case 2 from a multi-step mechanism. Response to imatinib varied from full remission to no response. Long term follow-up is necessary to evaluate the prognostic implications of these CT. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:105 / 110
页数:6
相关论文
共 50 条
  • [21] Bone marrow histopathology in chronic myelogenous leukemia (CML)-evaluation of distinctive features with clinical impact
    Thiele, J
    Kvasnicka, HM
    Fischer, R
    HISTOLOGY AND HISTOPATHOLOGY, 1999, 14 (04) : 1241 - 1256
  • [22] The immunomodulatory effects of Cordyceps sinensis on dendritic cells derived from chronic myelogenous leukemia (CML)
    Huang, Zhi-liang
    Jin, Jie
    Tong, Xiang-min
    Yang, Qun-zheng
    Gu, Bao-luo
    Wang, Jian-chao
    Yuedi-shen
    Xie, Jun-jun
    JOURNAL OF MEDICINAL PLANTS RESEARCH, 2011, 5 (24): : 5925 - 5932
  • [23] Cytogenetic response to imatinib treatment in Southern Brazilian patients with chronic myelogenous leukemia and variant Philadelphia chromosome
    Koshiyama, Dayane B.
    Capra, Marcelo E. Z.
    Paskulin, Giorgio A.
    Rosa, Rafael F. M.
    Oliveira, Ceres A. V.
    Vanelli, Tito
    Fogliatto, Laura M.
    Zen, Paulo R. G.
    ANNALS OF HEMATOLOGY, 2013, 92 (02) : 185 - 189
  • [24] Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL135INS
    Berman, Ellin
    Jhanwar, Suresh
    Hedvat, Cyrus
    Arcila, Maria E.
    Abdel-Wahab, Omar
    Levine, Ross
    Maloy, Molly
    Ma, Wanlong
    Albitar, Maher
    LEUKEMIA RESEARCH, 2016, 49 : 108 - 112
  • [25] Treatment-Free Remission: a New Therapeutic Goal in Chronic Myelogenous Leukemia
    Elsayed, Ahmed Gamal
    Srivastava, Roma
    Jamil, Muhammad Omer
    CURRENT ONCOLOGY REPORTS, 2017, 19 (12)
  • [26] Chronic myelogenous leukemia stem cells: What's new?
    Copland M.
    Current Hematologic Malignancy Reports, 2009, 4 (2) : 66 - 73
  • [27] Leukemogenesis and new therapy development:: the example of chronic myelogenous leukemia
    Étienne, G
    Mahon, FX
    BULLETIN DU CANCER, 2001, 88 (07) : 651 - 658
  • [28] Preleukemic phase of chronic myelogenous leukemia: morphologic and immunohistochemical characterization of 7 cases
    Le Aye, Le
    Loghavi, Sanam
    Young, Ken H.
    Siddiqi, Imran
    Yin, C. Cameron
    Routbort, Mark J.
    Liang, Mei
    Eilerman, Keith
    Medeiros, L. Jeffrey
    Brynes, Russell K.
    Bueso-Ramos, Carlos
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2016, 21 : 53 - 58
  • [29] THE GRAFT-VERSUS-LEUKEMIA (GVL) EFFECT AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA (CML)
    MARMONT, AM
    LEUKEMIA & LYMPHOMA, 1993, 11 : 221 - 226
  • [30] Current Status and Perspectives of Tyrosine Kinase Inhibitor Treatment in the Posttransplant Period in Patients with Chronic Myelogenous Leukemia (CML)
    Klyuchnikov, Evgeny
    Kroeger, Nicolaus
    Brummendorf, Tim H.
    Wiedemann, Bettina
    Zander, Axel Rolf
    Bacher, Ulrike
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (03) : 301 - 310